Abstract

http://ssrn.com/abstract=2173764
 


 



Government RX - Back to the Future in Science Funding? The Next Era in Drug Development


Michael J. Malinowski


Louisiana State University, Baton Rouge - Paul M. Hebert Law Center

November 10, 2012

University of Louisville Law Review, Vol. 51, No. 101, 2012

Abstract:     
Commercial free speech, recognized by U.S. federal courts in recent years in the pharmaceutical marketing context, has granted the biopharmaceutical sectors expansive marketing discretion and instilled industry independence from government regulation. However, after three decades of aggressive comingling of government, industry, and academia in biopharmaceutical research and development, the U.S. Government has announced an intervention to lift it out of doldrums of failure. The National Institutes of Health (NIH) has proposed a billion-dollar center to intervene in commercial drug development with the objective of lifting it out of a fifteen-year slump in productivity. This article questions the role of the U.S. government in human clinical research, drug development, and biopharmaceutical marketing post completion of the Human Genome Project (HGP). How much leeway should the biopharmaceutical sectors be granted under the doctrine of commercial free speech given the direct government investment in these sectors’ research and development and now intervention to make them commercially productive and to meaningfully improve human health? Should comingling government and industry give the U.S. government more leeway in regulating the outcome of the endeavor, especially when human health is at issue?

Number of Pages in PDF File: 26

Keywords: Pharmaceuticals, Government Funding, Technology Transfer, Biotechnology, Food and Drug Administration, International Conference on Harmonisation, Manhattan Project, Human Genome Project, NIH, National Institutes of Health, Francis Collins

JEL Classification: A00, B25, L50, I00, I18, O30, O40, O51, P10

Accepted Paper Series





Download This Paper

Date posted: November 12, 2012  

Suggested Citation

Malinowski, Michael J., Government RX - Back to the Future in Science Funding? The Next Era in Drug Development (November 10, 2012). University of Louisville Law Review, Vol. 51, No. 101, 2012. Available at SSRN: http://ssrn.com/abstract=2173764

Contact Information

Michael J. Malinowski (Contact Author)
Louisiana State University, Baton Rouge - Paul M. Hebert Law Center ( email )
440 Law Center Building
Baton Rouge, LA 70803
United States
225-578-8716 (Phone)
Feedback to SSRN


Paper statistics
Abstract Views: 205
Downloads: 13

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo4 in 0.485 seconds